Provention Bio Inc. (PRVB) is a clinical-stage biopharmaceutical company that develops immunotherapy treatments for autoimmune diseases and other chronic illnesses. The company's lead product candidate, teplizumab, is a potential treatment for the prevention or delay of type 1 diabetes in at-risk individuals. Teplizumab is a monoclonal antibody that targets the CD3 receptor on T cells, which are believed to play a key role in the destruction of insulin-producing beta cells in the pancreas. Provention Bio is also developing other immunotherapy treatments for the prevention and treatment of autoimmune diseases, including celiac disease and lupus. The company is headquartered in Oldwick, New Jersey, and as of September 2021, had a market capitalization of approximately $1.4 billion.
Provention Bio Inc. (PRVB) is a clinical-stage biopharmaceutical company that develops immunotherapy treatments for autoimmune diseases and other chronic illnesses. The company's lead product candidate, teplizumab, is a potential treatment for the prevention or delay of type 1 diabetes in at-risk individuals. Teplizumab is a monoclonal antibody that targets the CD3 receptor on T cells, which are believed to play a key role in the destruction of insulin-producing beta cells in the pancreas. Provention Bio is also developing other immunotherapy treatments for the prevention and treatment of autoimmune diseases, including celiac disease and lupus. The company is headquartered in Oldwick, New Jersey, and as of September 2021, had a market capitalization of approximately $1.4 billion.